RQM+ has launched its clinical trial services division to complete its complement of medtech contract research organisation (CRO) services.
Building upon 40 years of regulatory and quality expertise with the world’s largest global team, RQM+ now offers comprehensive laboratory testing, product development, reimbursement strategy and clinical trial services to support the entire product lifecycle for medical devices, digital therapeutics and diagnostics.
CEO Margaret Keegan said: “We have fully evolved our capabilities to become the medtech partner of choice for clients who want to reduce their commercialisation risk by providing all the services needed to launch their products in the market and keep them there. With the strongest regulatory consulting team in the medtech industry, our trusted experts provide support from the early development stage to commercialisation, all within one organisation. To deliver the high-quality clinical trials our clients expect, we are delighted to have someone with the depth of expertise that David Novotny brings to lead our trial services business.”
Novotny, chief operating officer for trial services, has more than 20 years of medtech clinical trial leadership experience in trial operations, consulting and device research across North America, Europe and Asia-Pacific. He previously held strategic leadership positions managing all trial services for several global medtech CROs.
Novotny said: “I am thrilled to join RQM+ to deliver on the vision of one seamless commercialisation platform to help medtech manufacturers mitigate risk. Our strategy includes new digital tools to ensure industry-leading transparency, speed, and agility, which will enable clients to make better data-driven decisions for patients.”
He holds a bachelor’s degree in physiology and business administration from the University of Iowa.
